-
Information-Publications
-
Self-assembly vascularized human cardiac organoids model cardiac diseases in petri dishes and in miceDetails
-
Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitorsDetails
-
Pathogenicity and Function Analysis of Two Novel SLC4A11 Variants in Patients With Congenital Hereditary Endothelial DystrophyDetails
-
AAV‐Mediated nuclear localized PGC1α4 delivery in muscle ameliorates sarcopenia and aging‐associated metabolic dysfunctionsDetails
-
Transferrin receptor levels and its rare variant are associated with human obesityDetails
-
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitorsDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands